Table 2.

Recently evaluated compounds with promising antagonistic activity against P2X7R.

Compound	Company	Study	Trial Phase	Completed	Observed Result	Observed Side Effect	Reference
A-438079	Abbott Laboratories	Neuropathic and inflammatory pain	Pre-clinical	Yes	Inhibited mechanical allodynia and effective in the formalin pain model	Not evaluated	[114]
A-740003	Abbott Laboratories	Neuropathic and inflammatory pain	Pre-clinical	Yes	Analgesic effect in inflammatory and neuropathic pain in rat	Not evaluated	[52]
A804598	Abbott Laboratories	Neuropathic and inflammatory pain	Pre-clinical	Yes	Analgesic effect in inflammatory and neuropathic pain in rat	Not evaluated	[25]
A847227	Abbott Laboratories	Anti-inflammatory and neuropathic pain	Pre-clinical	Yes	Antiallodynic activity and reduced the release of IL-1β in the zymosan mouse model	Not evaluated	[55]
AZ10606120	AstraZeneca	Ligand interaction and binding with P2X7R	Pre-clinical	Yes	Its molecule binds to a site different from which ATP binds, but it acts as a negative allosteric modulator	Not evaluated	[25]
AZ11645373	AstraZeneca	Selective potency	Pre-clinical	Yes	Inhibited hP2X7R and its pharmacologic properties	Not evaluated	[53]
AZD9056	AstraZeneca	Rheumatoid arthritis	II	Yes	No efficacy	Gastrointestinal (nausea, diarrhea, and vomiting)	[84]
CE-224,835	Pfizer	Rheumatoid arthritis	II	Yes	No efficacy	Gastrointestinal (nausea and diarrhea)	[83]
EVT-401	Evotec	The pharmacokinetic profile and pharmacodynamic effects	I	Yes	Safe and well tolerated	Not related	[78]
GSK314118A	Glaxo	Inflammatory pain	Pre-clinical	Yes	Analgesic activity in rat CFA model of inflammatory hyperalgesia	Not related	[55]